Recurrent Acute Myeloid Leukemia Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for recurrent acute myeloid leukemia in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

    This phase III trial compares the effect of xylitol dental wipes to dental wipes without xylitol for the reduction of bloodstream infection in children with acute myeloid leukemia (AML). Xylitol is a naturally occurring sugar compound found in fruits and vegetables. Xylitol has been shown to limit …

    Stage
    Phase 3
    Ages
    1 to 25
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Locations
    39 in total
    Run by
    Children's Oncology Group

    See if you can join NCT07022678 on ClinicalTrials.gov

  2. A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

    This phase I trial tests the safety, side effects, and best dose of ASTX727 and filgrastim for the treatment of children with high risk acute myeloid leukemia that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory) who have undergone allogenic…

    Stage
    Phase 1
    Ages
    Up to 21
    Site
    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
    Locations
    11 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT07012044 on ClinicalTrials.gov

  3. SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

    This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and has a mutation in the FLT3 gene along w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    4 in total
    Run by
    Uma Borate

    See if you can join NCT06222580 on ClinicalTrials.gov

  4. Tazemetostat and Palbociclib With CPX-351for R/R AML

    This is a two-part phase Ib dose escalation study to evaluate the safety and preliminary efficacy of the combination of tazemetostat and CPX-351 (Part 1) and of pre-treatment with palbociclib followed by CPX-351 (Part 2) for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). P…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    Run by
    Thomas Jefferson University

    See if you can join NCT05627232 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.